Maryland's Prescription Drug Affordability Board: A Systemic Approach to Tackling Pharmaceutical Price Gouging
Original framing: “STAT+: Maryland state affordability board places a price cap on Ozempic” — STAT News
The issue of pharmaceutical price gouging has a long history, dating back to the 19th century when pharmaceutical companies first began to exploit patent laws to maximize profits. In the 20th century, the US government implemented policies that allowed pharmaceutical companies to charge high prices for life-saving medications, leading to widespread price gouging. Today, the issue persists, with many pharmaceutical companies continuing to prioritize profits over people.
The issue of pharmaceutical price gouging is a complex and multifaceted problem that requires a comprehensive and systemic approach to address.
By prioritizing people over profits in healthcare policy, we can begin to address the systemic inequalities that perpetuate health disparities. This requires investing in evidence-based policy interventions, prioritizing community well-being over corporate profiteering, and amplifying the voices of marginalized communities. By doing so, we can create a more just and equitable healthcare system that prioritizes people over profits.